SkyePharma and First Horizon Extend Agreement for Novel Formulation of Fenofibrate
February 01 2005 - 6:00AM
PR Newswire (US)
SkyePharma and First Horizon Extend Agreement for Novel Formulation
of Fenofibrate LONDON, Feb. 1 /PRNewswire-FirstCall/ -- SkyePharma
PLC (NASDAQ:SKYE) ( LSE: SKP) announces today that it has extended
an agreement with First Horizon Pharmaceutical Corporation ("First
Horizon", Nasdaq: FHRX) originally signed in May 2004 in connection
with SkyePharma's novel formulation of fenofibrate, currently under
review by the US Food and Drug Administration ("FDA"). Subject to
FDA approval, the amended agreement would now permit First Horizon
to launch the novel fenofibrate product in the first half of 2005.
Michael Ashton, SkyePharma's Chief Executive Officer, said: "We are
delighted by this demonstration of First Horizon's continuing
commitment." SkyePharma PLC develops pharmaceutical products
benefiting from world-leading drug delivery technologies that
provide easier-to-use and more effective drug formulations. There
are now nine approved products incorporating three from
SkyePharma's five technologies in the areas of oral, injectable,
inhaled and topical delivery, supported by advanced solubilisation
capabilities. For more information, visit
http://www.skyepharma.com/. Except for the historical information
herein, the matters discussed in this news release include
forward-looking statements that may involve a number of risks and
uncertainties. Actual results may vary significantly based upon a
number of factors, which are described in SkyePharma's 20-F and
other documents on file with the SEC. These include without
limitation risks in obtaining and maintaining regulatory approval
for existing, new or expanded indications for its products, other
regulatory risks, risks relating to SkyePharma's ability to
manufacture pharmaceutical products on a large scale, risks that
customer inventory will be greater than previously thought, risks
concerning SkyePharma's ability to manage growth, SkyePharma's
marketing partners' ability to market a pharmaceutical product on a
large scale and manage their sales and marketing organisation and
maintain or expand sales and market share for its products, risks
relating to the ability to ensure regulatory compliance, risks
related to the research, development and regulatory approval of new
pharmaceutical products, risks related to research and development
costs and capabilities, market acceptance of and continuing demand
for SkyePharma's products and the impact of increased competition,
risks associated with anticipated top and bottom line growth and
the possibility that upside potential will not be achieved,
competitive products and pricing, and risks associated with the
ownership and use of intellectual property rights. SkyePharma
undertakes no obligation to revise or update any such
forward-looking statement to reflect events or circumstances after
the date of this release. For further information please contact:
SkyePharma PLC +44 207 491 1777 Michael Ashton, Chief Executive
Officer Peter Laing, Director of Corporate Communications +44
205-491 5124 Sandra Haughton, US Investor Relations +1 212 753 5780
Buchanan Communications +44 207 466 5000 Tim Anderson / Mark Court
DATASOURCE: SkyePharma PLC CONTACT: Michael Ashton, Chief Executive
Officer, +44-207-491-1777, Peter Laing, Director of Corporate
Communications, +44-205-491-5124, Sandra Haughton, US Investor
Relations, +1-212-753-5780, all of SkyePharma PLC, Tim Anderson and
Mark Court of Buchanan Communications, +44-207-466-5000 for
SkyePharma PLC Web site: http://www.skyepharma.com/
Copyright